Laboratório de Agentes Infecciosos e Vetores, Centro das Ciências Biológicas e da Saúde, Universidade Federal do Oeste da Bahia, Barreiras, Brazil.
Programa de Pós-graduação em Biologia e Biotecnologia de Microrganismos, Universidade Estadual de Santa Cruz, Barreiras, Brazil.
Front Immunol. 2020 Jun 18;11:1252. doi: 10.3389/fimmu.2020.01252. eCollection 2020.
(DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Although there is only one vaccine formulation licensed for use in humans, there are other vaccine formulations under development that apply different strategies. In this review, we present information about anti-dengue vaccine formulations regarding development, pre-clinical tests, and clinical trials. The improvement in vaccine development against dengue is much needed, but it should be considered that the correlate of protection is still uncertain. Neutralizing antibodies have been proposed as a correlate of protection, but this ignores the key role of T-cell mediated immunity in controlling DENV infection. It is important to confirm the accurate correlate of protection against DENV infection, and also to have other anti-dengue vaccine formulations licensed for use.
(DENV) 是一种虫媒病毒（节肢动物传播的病毒）。四种血清型的 DENV 可引起登革热这种传染病，每年在全球范围内影响近 4 亿人。虽然只有一种登革热疫苗制剂获得许可用于人类，但还有其他疫苗制剂正在开发中，采用不同的策略。在这篇综述中，我们介绍了抗登革热疫苗制剂的信息，包括开发、临床前试验和临床试验。需要改进登革热疫苗的开发，但应考虑到保护的相关性仍然不确定。中和抗体已被提议作为保护的相关性，但这忽略了 T 细胞介导的免疫在控制 DENV 感染中的关键作用。确认针对 DENV 感染的准确保护相关性非常重要，同时也需要获得其他许可用于登革热的疫苗制剂。
